Document is current
Any future updates will be listed below
-
Authors
van de Haar, Joris
Ma, Xuhui
Ooft, Salo N. http://orcid.org/0000-0002-3990-3376
van der Helm, Pim W.
Hoes, Louisa R.
Mainardi, Sara
Pinato, David J. http://orcid.org/0000-0002-3529-0103
Sun, Kristi
Salvatore, Lisa
Tortora, Giampaolo http://orcid.org/0000-0002-1378-4962
Zurlo, Ina Valeria
Leo, Silvana
Giampieri, Riccardo
Berardi, Rossana
Gelsomino, Fabio http://orcid.org/0000-0001-7979-4795
Merz, Valeria
Mazzuca, Federica
Antonuzzo, Lorenzo
Rosati, Gerardo
Stavraka, Chara
Ross, Paul
Rodriquenz, Maria Grazia
Pavarana, Michele
Messina, Carlo
Iveson, Timothy
Zoratto, Federica
Thomas, Anne
Fenocchio, Elisabetta http://orcid.org/0000-0001-6679-0955
Ratti, Margherita
Depetris, Ilaria
Cergnul, Massimiliano
Morelli, Cristina
Libertini, Michela
Parisi, Alessandro
De Tursi, Michele
Zanaletti, Nicoletta
Garrone, Ornella
Graham, Janet
Longarini, Raffaella
Gobba, Stefania Maria
Petrillo, Angelica
Tamburini, Emiliano
La Verde, Nicla
Petrelli, Fausto http://orcid.org/0000-0001-9639-4486
Ricci, Vincenzo
Wessels, Lodewyk F. A. http://orcid.org/0000-0002-1656-6995
Ghidini, Michele
Cortellini, Alessio http://orcid.org/0000-0002-1209-5735
Voest, Emile E. http://orcid.org/0000-0001-8249-9586
Valeri, Nicola http://orcid.org/0000-0002-5426-5683
- License Information
-
More Information
Article History
Received: 11 January 2022
Accepted: 26 January 2023
First Online: 2 March 2023
Competing interests
: E.E.V. reports research grants from Roche, Pfizer, GSK, Novartis, Merck, Bristol Myers Squibb, AstraZeneca, Amgen, Bayer, Sanofi, Seagen, Janssen, Eisai, Ipsen and Lilly. He is a founder, strategic advisor and shareholder of MOSAIC Therapeutics and nonexecutive, independent director and shareholder of Sanofi, all outside the submitted work. L.F.A.W. reports grants from Genmab, outside the submitted work. A.C. received grant consultancy fees from MSD, AstraZeneca, Oncoc4 and IQVIA. He also declares speaker’s fees from Eisai and AstraZeneca. A.P. received personal fees from Lilly, Servier, Merck, Amgen, Bristol Myers Squibb and MSD. A.T. declares speaker bureau fees from Bristol Myers Squibb and Servier. C.S. received honoraria from the speaker bureau at Servier. D.J.P. received lecture fees from ViiV Healthcare, Bayer Healthcare, Bristol Myers Squibb, Roche, Eisai and the Falk Foundation, travel expenses from Bristol Myers Squibb and Bayer Healthcare, consulting fees for Mina Therapeutics, H3B, Eisai, Roche, DaVolterra, Mursla, Exact Sciences, Avamune and AstraZeneca and research funding (to institution) from MSD, Bristol Myers Squibb and GSK. F.G. received honoraria for speaker/advisory roles from Servier, Lilly, IQVIA, Merck Serono, Bayer, Amgen and Bristol Myers Squibb outside the present work. F.M. received fees from the speaker bureaux of Servier, Amgen, Novartis, MSD and Merck. G.T. took part in the advisory boards for Bristol Myers Squibb, AstraZeneca, MSD, Merck and Servier. J.G. received honoraria for educational events organized by Servier. L.S. received speaker and consultancy fees from MSD, AstraZeneca, Servier, Bayer, Merck, Amgen and Pierre-Fabre. M.G.R. received consultancy fees from Roche. M.G. received grants and advisory board fees from Merck, Servier, Lilly, Amgen and Italfarmaco. N.L.V. received fees and honoraria from Eisai, MSD, Roche, Novartis, AstraZeneca, GSK, Pfizer, Gentili and Lilly. N.V. received honoraria from Merck Serono, Pfizer, Bayer, Lilly and Servier, consultancy fees from BenevolentAI and grants (institutional) from Roche and BenevolentAI. N.Z. declares personal fees from Bayer and Eisai. O.G. reports consulting fees from Eisai, Lilly, MSD and Seagen and payment or honoraria for lectures, presentations, speaker bureaux fees, manuscript writing or educational events from Novartis, Lilly and Eisai. P.R. received grants from Bayer and Sanofi, honoraria for advisory boards from AstraZeneca, Eisai, Servier and Sirtex, speaking fees from Amgen, Boston Scientific, HMP Education, Eisai, Roche and Servier and travel conference support from Bayer, Roche, Ipsen and Servier. R.G. took part in advisory boards for Merck, Amgen, Servier and Bayer. R.B. declares consultancies, advisory board roles and/or institutional donations from AstraZeneca, Boehringer Ingelheim, Novartis, MSD, Otsuka, Lully, Roche, Amgen, GSK and Eisai. T.I. received honoraria for educational symposia run by Servier. All other authors declare no competing interests.
